FDA Approves Secnidazole for BV, Trichomoniasis in Adolescents

FDA Approves Secnidazole for BV, Trichomoniasis in Adolescents

The Meals and Drug Administration has authorized secnidazole for the remedy of bacterial vaginosis (BV) and trichomoniasis in sufferers aged 12 years and older.

The antimicrobial agent, marketed as Solosec, was first authorized in 2017 as a remedy for BV in grownup girls. In 2021, it was authorized for the remedy of trichomoniasis in grownup women and men.

Lupin Prescription drugs, which manufactures the drug, introduced the expanded approval for adolescents in a information launch.

The treatment is supposed to be taken as a single dose. It is available in a packet that must be sprinkled onto applesauce, yogurt, or pudding and consumed with out chewing or crunching.

The remedy choice might assist “tackle gaps in care associated to adherence,” mentioned Tom Merriam, an government director with Lupin.

Bacterial vaginosis is a typical vaginal an infection. Trichomoniasis is the most typical nonviral, curable STI in america. Sexual companions of sufferers with trichomoniasis may be handled on the identical time.

Vulvovaginal candidiasis is without doubt one of the potential unwanted effects of secnidazole remedy, the drug’s label notes.

This story initially appeared on MDedge.com, a part of the Medscape Skilled Community.

Learn Extra

Leave a Comment

Your email address will not be published.